Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0090
0.00 (0.00%)
Feb 11, 2026, 1:12 PM EST

Evofem Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-5.43-8.8652.98-76.7-205.19-142.31
Depreciation & Amortization
0.770.650.481.021.020.3
Loss (Gain) From Sale of Assets
0.740.732.510.93--
Stock-Based Compensation
0.310.851.193.318.912.7
Other Operating Activities
-3.161.88-70.85-4.9838.0339.71
Change in Accounts Receivable
0.96-4.09-4.615.32-5.38-1.07
Change in Inventory
-0.460.062.111.57-0.02-6.01
Change in Accounts Payable
-2.06-0.914.094.47-04.13
Change in Other Net Operating Assets
3.95.813.14-5.3515.99-12.28
Operating Cash Flow
-4.43-3.89-8.97-70.41-146.67-104.83
Capital Expenditures
-0-0.01-0-0.34-2.94-2.25
Cash Acquisitions
-0.1-0.56----
Divestitures
----0.250.25
Investment in Securities
-----8.23
Investing Cash Flow
-0.11-0.57-0-0.34-2.696.23
Short-Term Debt Issued
-0.45.64--50
Long-Term Debt Issued
---11.5--
Total Debt Issued
2.810.45.6411.5-50
Long-Term Debt Repaid
--0.78-1.15-5.89--
Total Debt Repaid
-0.89-0.78-1.15-5.89--
Net Debt Issued (Repaid)
1.91-0.394.495.61-50
Issuance of Common Stock
550.2957.5581.99107.97
Repurchase of Common Stock
----0.02-0.33-2.87
Other Financing Activities
-1---1.2-0.97-0.87
Financing Cash Flow
4.654.624.7861.9490.69154.23
Net Cash Flow
0.120.16-4.2-8.81-58.6655.63
Free Cash Flow
-4.43-3.9-8.97-70.75-149.61-107.08
Free Cash Flow Margin
-25.01%-20.14%-49.25%-420.21%-1814.73%-24009.64%
Free Cash Flow Per Share
-0.04-0.05-0.01-151.84-2142.80-2989.73
Cash Interest Paid
0.160.160.340.71.39-
Cash Income Tax Paid
0.010.0100.030.010
Levered Free Cash Flow
-7.17-3.88-7.08-37.99-69.98-91.42
Unlevered Free Cash Flow
-5.56-2.27-5.43-36.68-67.02-90.12
Change in Working Capital
2.340.874.736.0210.58-15.23
Source: S&P Global Market Intelligence. Standard template. Financial Sources.